Drug intelligence / Profile preview

SRRM2-CAR-T

Development stage: Unknown
Lead developer: Eximmium Biotechnologies
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SRRM2-CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Eximmium Biotechnologies. It is engineered to target Serine/arginine repetitive matrix protein 2 (SRRM2), a protein involved in pre-mRNA splicing that is aberrantly expressed on the surface of certain malignant cells. By binding to SRRM2, the CAR-T cells are activated to induce T-cell-mediated cytotoxicity against the tumor cells. The therapy is currently being investigated in Phase 1 clinical trials for the treatment of multiple myeloma and is in preclinical development for pancreatic cancer.

Other names: SRRM2 CAR-TSRRM-2 CAR-TSRRM 2 CAR-T

Targets

SRRM2 (Serine/arginine repetitive matrix protein 2)

Beyond the preview

Go deeper on SRRM2-CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRRM2-CAR-T.

Explore the full profile